Oruka Therapeutics (NASDAQ:ORKA) Given “Buy” Rating at HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. They presently have a $120.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 43.14% from the company’s current price.

Other equities research analysts have also issued reports about the stock. UBS Group lifted their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $128.91.

Oruka Therapeutics Price Performance

ORKA traded down $6.10 during mid-day trading on Thursday, hitting $83.83. The stock had a trading volume of 420,106 shares, compared to its average volume of 1,098,693. The stock’s fifty day simple moving average is $96.79 and its 200-day simple moving average is $75.32. The firm has a market capitalization of $5.55 billion, a price-to-earnings ratio of -41.39 and a beta of -0.34. Oruka Therapeutics has a 1-year low of $14.89 and a 1-year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, research analysts expect that Oruka Therapeutics will post -2.42 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at $84,996,011.40. This trade represents a 7.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86. Following the completion of the transaction, the insider directly owned 31,771 shares of the company’s stock, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 122,950 shares of company stock valued at $11,528,806 in the last quarter. Company insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Engineers Gate Manager LP bought a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $350,000. Arizona State Retirement System grew its position in shares of Oruka Therapeutics by 45.0% in the 2nd quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock valued at $825,000 after acquiring an additional 2,691 shares during the period. Nykredit A S bought a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $29,000. Braidwell LP bought a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $26,473,000. Finally, Natural Investments LLC bought a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $202,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics News Summary

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and set a $165 price target, implying substantial potential upside from the referenced $89.93 level. Tickerreport analyst rating article
• Positive Sentiment: HC Wainwright also reaffirmed its “buy” rating and assigned a $120 price target, indicating continued analyst confidence in Oruka’s pipeline and valuation. StreetInsider analyst rating article
• Positive Sentiment: Oruka reported encouraging Week 28 results from the Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis. PASI 100 responses increased to 71.4% and PASI 90 responses to 87.3%, despite no additional dosing after Week 4, suggesting durable and deepening treatment effects. Oruka EVERLAST-A Week 28 results
• Positive Sentiment: Placebo-crossover patients achieved PASI 90 and PASI 100 response rates comparable to patients initially treated with ORKA-001, while the therapy continued to show a favorable safety and tolerability profile. Additional EVERLAST-A data are expected in December 2026, with EVERLAST-B results expected in the fourth quarter. MarketScreener trial results
• Negative Sentiment: Oruka shares fell after the Week 28 release despite improving psoriasis responses. The reaction suggests investors may have already anticipated strong data, or may be focused on the need for additional validation from upcoming 52-week and follow-on trial results. Yahoo Finance market reaction

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.